ARS Pharmaceuticals, Inc. (SPRY)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, ARS Pharmaceuticals, Inc. reported revenue of $84.28M, down 5.5% from the prior year. The company ran a net loss, with a net margin of -203.3%. It held $327.65M in total assets against $213.39M in total liabilities.
Key ratios (FY2025)
-212.9%
Operating margin
-203.3%
Net margin
-149.9%
Return on equity
-5.5%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $84.28M | $89.15M | $30.0K | $1.32M | $5.51M | — | — |
| Cost of Revenue | — | — | $0 | — | — | — | — |
| Operating Income | -$179.45M | -$3.08M | -$67.52M | -$35.52M | -$19.45M | -$32.92M | — |
| Net Income | -$171.30M | $8.00M | -$54.37M | -$34.68M | -$20.24M | -$32.95M | — |
| EPS (Diluted) | $-1.74 | $0.08 | $-0.57 | $-0.87 | $-0.70 | — | — |
| Total Assets | $327.65M | $351.15M | $233.19M | $281.44M | $61.45M | $394.80M | — |
| Total Liabilities | $213.39M | $94.36M | $2.43M | $8.55M | $16.68M | $11.93M | — |
| Shareholders' Equity | $114.26M | $256.80M | $230.76M | $272.89M | -$31.27M | -$14.05M | -$58.78M |
| Cash & Equivalents | $41.32M | $50.82M | $70.97M | $210.52M | $60.06M | $386.57M | — |
| Operating Cash Flow | -$170.87M | $13.55M | -$59.27M | -$40.08M | -$17.56M | -$31.20M | — |
| Capital Expenditures | $339.0K | $563.0K | $175.0K | $199.0K | $55.0K | $917.0K | — |
| Shares Outstanding | 99.29M | 97.95M | 96.41M | 93.94M | 30.37M | 34.70M | — |